Cargando…

Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder

OBJECTIVE: To describe leptomeningeal blood-barrier impairment reflected by MRI gadolinium-enhanced lesions in patients with aquaporin-4 immunoglobulin G (AQP4-IgG)–positive neuromyelitis optica spectrum disorder (NMOSD). METHODS: A retrospective case series of 11 AQP4-IgG–positive NMOSD patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asgari, Nasrin, Flanagan, Eoin P., Fujihara, Kazuo, Kim, Ho Jin, Skejoe, Hanne P., Wuerfel, Jens, Kuroda, Hiroshi, Kim, Su Hyun, Maillart, Elisabeth, Marignier, Romain, Pittock, Sean J., Paul, Friedemann, Weinshenker, Brian G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400808/ https://www.ncbi.nlm.nih.gov/pubmed/28451627 http://dx.doi.org/10.1212/NXI.0000000000000343

Ejemplares similares

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
por: Hor, Jyh Yung, et al.
Publicado: (2020)

Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998–2008, 2007–2014)
por: Asgari, Nasrin, et al.
Publicado: (2019)

Leptomeningeal and Intraparenchymal Blood Barrier Disruption in a MOG-IgG-Positive Patient
por: Mohseni, Seyed Hamidreza, et al.
Publicado: (2018)

Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
por: Weinshenker, Brian G, et al.
Publicado: (2023)

Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study
por: Asgari, Nasrin, et al.
Publicado: (2013)

Placebo-controlled study in neuromyelitis optica—Ethical and design considerations
por: Cree, Bruce AC, et al.
Publicado: (2015)

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
por: Marignier, Romain, et al.
Publicado: (2021)

Differential diagnosis of neuromyelitis optica spectrum disorders
por: Kim, Sung-Min, et al.
Publicado: (2017)

Update on biomarkers in neuromyelitis optica
por: Melamed, Esther, et al.
Publicado: (2015)

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder
por: Aktas, Orhan, et al.
Publicado: (2023)

Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology
por: Fujihara, Kazuo, et al.
Publicado: (2020)

NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
por: Weinshenker, Brian G., et al.
Publicado: (2006)

Neuromyelitis optica spectrum disorders: still evolving and broadening
por: Fujihara, Kazuo
Publicado: (2019)

Case Report: In Situ Expression of a Proliferation-Inducing Ligand in Neuromyelitis Optica
por: Baert, Laurie, et al.
Publicado: (2021)

Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Interferon Alpha Association with Neuromyelitis Optica
por: Asgari, Nasrin, et al.
Publicado: (2013)

SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab
por: Bennett, Jeffrey L., et al.
Publicado: (2023)

Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial
por: Bennett, Jeffrey L., et al.
Publicado: (2022)

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders
por: Palace, Jacqueline, et al.
Publicado: (2019)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
por: Schanda, Kathrin, et al.
Publicado: (2015)

A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica
por: Giovannelli, Jonathan, et al.
Publicado: (2021)

Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders
por: Redenbaugh, Vyanka, et al.
Publicado: (2021)

Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography
por: Bennett, JL, et al.
Publicado: (2015)

CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage
por: Hyun, Jae-Won, et al.
Publicado: (2022)

Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study
por: Demuth, Stanislas, et al.
Publicado: (2022)

Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder
por: Wingerchuk, Dean M., et al.
Publicado: (2021)

Ependyma: a new target for autoantibodies in neuromyelitis optica?
por: Bigotte, Maxime, et al.
Publicado: (2022)

Spectrum of sublytic astrocytopathy in neuromyelitis optica
por: Guo, Yong, et al.
Publicado: (2021)

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
por: Wingerchuk, Dean M., et al.
Publicado: (2015)

Imaging the Visual Pathway in Neuromyelitis Optica
por: Pfueller, Caspar F., et al.
Publicado: (2011)

Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
por: Trebst, Corinna, et al.
Publicado: (2013)

Retinal Optical Coherence Tomography in Neuromyelitis Optica
por: Oertel, Frederike Cosima, et al.
Publicado: (2021)

Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica
por: Pasquier, Baptiste, et al.
Publicado: (2019)

Challenges and opportunities in designing clinical trials for neuromyelitis optica
por: Weinshenker, Brian G., et al.
Publicado: (2015)

A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”
por: Wingerchuk, Dean M., et al.
Publicado: (2022)

Olfactory Dysfunction in Patients with Neuromyelitis Optica
por: Schmidt, Felix, et al.
Publicado: (2013)

Neuromyelitis Optica
por: Misra, M. C., et al.
Publicado: (1953)

New Insights into Neuromyelitis Optica
por: Kim, Woojun, et al.
Publicado: (2011)

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)

Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review
por: Papp, Viktoria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vjtea96ak9t6q7rj9ooo6odqkj